Proton Rahman

Dr. Proton Rahman

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
PRProton Rahman
Proton Rahman
JEJ T Elder
J T Elder
Psoriasis and psoriatic arthritis (PsA) are interrelated disorders, as most patients with PsA also have psoriasis. Thus it is not surprising that epidemiological and immunogenetic studies have uncovered important links between these two disorders. Both disorders are highly heritable, and the prevalence of psoriasis is 19 times higher among first degree relatives of probands with PsA compared with the general population. Multiple human leucocyte antigen (HLA) associations are shared between psoriasis and PsA, though the magnitudes of these associations differ between the diseases. Genome-wide linkage studies have noted overlapping regions of significance for these two disorders within and outside the major histocompatibility complex (MHC) region. Thus, exploration of the genetic basis of psoriasis will likely strengthen the contention of an underlying genetic susceptibility for PsA and vice versa.

27 March 2008 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
PRProton Rahman
Proton Rahman
RIRobert Davies Inman
Robert Davies Inman
DGDafna D. Gladman
Dafna D. Gladman
JRJeff P. Reeve
Jeff P. Reeve
LPLynette Peddle
Lynette Peddle
WMWalter P. Maksymowych
Walter P. Maksymowych
Objective: Recent studies have shown that a nonsynonymous single‐nucleotide polymorphism (SNP) (Arg381Gln; rs11209026) in the interleukin‐23 receptor (IL‐23R) gene on chromosome 1p31 is associated with Crohn's disease and psoriasis. Given the clinical and immunologic overlap between ankylosing spondylitis (AS) and these diseases, and the potential function of this candidate SNP, this study was undertaken to examine the association of IL‐23R variants with AS in multiple Canadian populations.Methods: We examined 3 cohorts of AS patients from established rheumatic disease centers in Canada. The majority of AS patients were Caucasians of northern European descent, and all patients satisfied the modified New York classification criteria for AS or for juvenile spondylarthritis. We examined 424 AS probands and 401 controls from Alberta, 251 AS probands and 122 controls from Toronto, and 121 AS probands and 219 controls from Newfoundland. Ten IL‐23R SNPs were genotyped, 9 of which were incorporated in the haplotype analysis. Allele and haplotype associations were calculated using the WHAP software package.Pvalues for haplotype associations were calculated using a permutation test.Results: The primary SNP of interest in a previous study of inflammatory bowel disease (IBD) (Arg381Gln; rs11209026) was found to be protective against AS in the Newfoundland population (P= 0.04) and in the Toronto population (P= 0.04) in single‐marker univariate analysis. The strongest association, however, was with SNP rs11465804 (P= 0.007 for the Newfoundland population andP= 0.0007 for the Toronto population). A 3‐marker sliding window omnibus test revealed a significant association with markers rs10489629, rs2201841, and rs11465804 in both the Newfoundland population (P= 0.04) and the Alberta population (P= 0.034). Our results were independent of the IBD and psoriasis status of the AS patients.Conclusion: This concurrent analysis of 3 distinct AS populations and their regional controls demonstrates a disease association with the IL‐23R locus and implicates the same polymorphisms associated with IBD and psoriasis.

15 March 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
PNPeter Nash
Peter Nash
PMPhilip J. Mease
Philip J. Mease
IMIain B. McInnes
Iain B. McInnes
PRProton Rahman
Proton Rahman
CRChristopher T. Ritchlin
Christopher T. Ritchlin
LPLuminita Pricop
Luminita Pricop
The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study ( ClinicalTrials.gov NCT01989468). Patients (≥ 18 years of age; N = 414) with active PsA were randomized 1:1:1 to subcutaneous (s.c.) secukinumab 300 mg, 150 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and every 4 weeks thereafter. Per clinical response, placebo-treated patients were re-randomized to s.c. secukinumab 300 or 150 mg at week 16 (nonresponders) or week 24 (responders) and stratified at randomization by prior anti-tumor necrosis factor (TNF) therapy (anti-TNF-naïve, 68.1%; intolerant/inadequate response (anti-TNF-IR), 31.9%). The primary endpoint was the proportion of patients achieving at least 20% improvement in American College of Rheumatology response criteria (ACR20) at week 24. Autoinjector usability was evaluated by Self-Injection Assessment Questionnaire (SIAQ). Overall, 92.1% (300 mg), 91.3% (150 mg), and 93.4% (placebo) of patients completed 24 weeks, and 84.9% (300 mg) and 79.7% (150 mg) completed 52 weeks. In the overall population (combined anti-TNF-naïve and anti-TNF-IR), ACR20 response rate at week 24 was significantly higher in secukinumab groups (300 mg, 48.2% (p < 0.0001); 150 mg, 42% (p < 0.0001); placebo, 16.1%) and was sustained through 52 weeks. SIAQ results showed that more than 93% of patients were satisfied/very satisfied with autoinjector usage. Secukinumab was well tolerated with no new or unexpected safety signals reported. Secukinumab provided sustained improvements in signs and symptoms in active PsA patients through 52 weeks. High acceptability of autoinjector was observed. The safety profile was consistent with that reported previously. ClinicalTrials.gov NCT01989468 . Registered 21 November 2013. EudraCT 2013–004002-25 . Registered 17 December 2013.

4 January 2007 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
CBChristopher Butt
Christopher Butt
SLSooyeol Lim
Sooyeol Lim
CGCelia M.T. Greenwood
Celia M.T. Greenwood
PRProton Rahman
Proton Rahman
Background: Angiogenesis appears to be a first-order event in psoriatic arthritis (PsA). Among angiogenic factors, the cytokines vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factors 1 and 2 (FGF1 and FGF2) play a central role in the initiation of angiogenesis. Most of these cytokines have been shown to be upregulated in or associated with psoriasis, rheumatoid arthritis (RA) or ankylosing spondylitis (AS). As these diseases share common susceptibility associations with PsA, investigation of these angiogenic factors is warranted. Methods: Two hundred and fifty-eight patients with PsA and 154 ethnically matched controls were genotyped using a Sequenom chip-based MALDI-TOF mass spectrometry platform. Four SNPs in the VEGF gene, three SNPs in the EGF gene and one SNP each in FGF1 and FGF2 genes were evaluated. Statistical analysis was performed using Fisher's exact test, and the Cochrane-Armitage trend test. Associations with haplotypes were estimated by using weighted logistic models, where the individual haplotype estimates were obtained using Phase v2.1. Results: We have observed an increased frequency in the T allele of VEGF +936 (rs3025039) in control subjects when compared to our PsA patients [Fisher's exact p-value = 0.042; OR 0.653 (95% CI: 0.434, 0.982)]. Haplotyping of markers revealed no significant associations. Conclusion: The T allele of VEGF in +936 may act as a protective allele in the development of PsA. Further studies regarding the role of pro-angiogenic markers in PsA are warranted.

1 September 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PRProton Rahman
Proton Rahman
SBS. Bartlett
S. Bartlett
FSF. Siannis
F. Siannis
FPF.J. Pellett
F.J. Pellett
VFV.T. Farewell
V.T. Farewell
DGD.D. Gladman
D.D. Gladman

1 September 2003
Verified
Journal Article
Closed access
DGDafna D Gladman
Dafna D Gladman
MUMurray Urowitz
Murray Urowitz
PRProton Rahman
Proton Rahman
DIDominique Ibañez
Dominique Ibañez
LTLai-Shan Tam
Lai-Shan Tam